- Company info
- News & events
- Investors
- Contacts & help
Share Price
Latest
ReNeuron presents key pre-clinical efficacy data with ReN009 stem cell therapy at leading UK diabetes conference
ReNeuron announces that it has raised approximately £4.7 million, before expenses, from existing and new institutional and qualifying individual shareholders via a placing of 94,400,000 new ordinary shares, at a price of 5 pence per share
ReNeuron announces that its ongoing US collaboration with the Schepens Eye Research Institute at Harvard Medical School will benefit from an unrestricted grant to advance retinal research at Schepens from a leading US specialty healthcare company